Blockade of chronic graft-versus-host disease by alloantigen-induced CD4+CD25+Foxp3+ regulatory T cells in nonlymphopenic hosts
- PMID: 17684039
- DOI: 10.1189/jlb.0407227
Blockade of chronic graft-versus-host disease by alloantigen-induced CD4+CD25+Foxp3+ regulatory T cells in nonlymphopenic hosts
Abstract
CD4(+)CD25(+) regulatory T cells (Tregs) are well known to suppress immunopathology induced in lymphopenic animals following T cell reconstitution, including acute graft-versus-host disease (GVHD) post-bone marrow transplantation. The regulatory potential of this subset in nonlymphopenic hosts and in chronic, Th2-mediated GVHD is less clear. We have generated alloantigen-specific cells from CD4(+)CD25(+) populations stimulated with MHC-disparate dendritic cells and found them to express a stable Treg forkhead box p3(+) phenotype with enhanced suppressive activity mediated by cell contact. When transferred into nonlymphopenic F1 hosts, nonspecific Tregs proliferated as rapidly as CD4(+)CD25(-) cells but displayed distinct growth kinetics in vitro. Tregs, expanded in response to alloantigen in vitro, displayed greatly enhanced suppressive activity, which was partially antigen-specific. They were effective inhibitors of chronic GVHD, blocking donor cell engraftment, splenomegaly, autoantibody production, and glomerulonephritis. CD25(+) and CD25(-) cells were equally susceptible to inhibition by immunosuppressive drugs targeting TCR signaling and rapamycin, but Tregs were resistant to inhibition by dexamethasone. The data indicate that alloantigen-driven expansion, rather than homeostatic proliferation, is key to the effectiveness of CD4(+)CD25(+) Tregs in GVHD and suggest that cellular therapy with alloantigen-induced Tregs in combination with glucocorticoid treatment would be effective in prevention of chronic GVHD after immune reconstitution.
Similar articles
-
Dendritic cells expand antigen-specific Foxp3+ CD25+ CD4+ regulatory T cells including suppressors of alloreactivity.Immunol Rev. 2006 Aug;212:314-29. doi: 10.1111/j.0105-2896.2006.00422.x. Immunol Rev. 2006. PMID: 16903923 Review.
-
Transforming growth factor-beta1-induced CD4+CD25+ regulatory T cells in vitro reverse and prevent a murine lupus-like syndrome of chronic graft-versus-host disease.Br J Dermatol. 2008 Jun;158(6):1197-209. doi: 10.1111/j.1365-2133.2008.08555.x. Epub 2008 Apr 10. Br J Dermatol. 2008. PMID: 18410422
-
Alloantigen specific T regulatory cells in transplant tolerance.Int Immunopharmacol. 2009 May;9(5):570-4. doi: 10.1016/j.intimp.2009.01.016. Epub 2009 Jan 29. Int Immunopharmacol. 2009. PMID: 19539571 Review.
-
Combined therapy of CD4(+)CD25(+) regulatory T cells with low-dose sirolimus, but not calcineurin inhibitors, preserves suppressive function of regulatory T cells and prolongs allograft survival in mice.Int Immunopharmacol. 2009 May;9(5):553-63. doi: 10.1016/j.intimp.2009.01.033. Epub 2009 Feb 8. Int Immunopharmacol. 2009. PMID: 19539558
-
The effect of immunosuppressive drug rapamycin on regulatory CD4+CD25+Foxp3+T cells in mice.Transpl Immunol. 2007 Apr;17(3):153-61. doi: 10.1016/j.trim.2007.01.002. Epub 2007 Jan 24. Transpl Immunol. 2007. PMID: 17331841
Cited by
-
Autophagy-dependent regulatory T cells are critical for the control of graft-versus-host disease.JCI Insight. 2016 Sep 22;1(15):e86850. doi: 10.1172/jci.insight.86850. JCI Insight. 2016. PMID: 27699243 Free PMC article.
-
IL-2 enhances ex vivo-expanded regulatory T-cell persistence after adoptive transfer.Blood Adv. 2020 Apr 28;4(8):1594-1605. doi: 10.1182/bloodadvances.2019001248. Blood Adv. 2020. PMID: 32311015 Free PMC article.
-
Extracorporeal photopheresis in the treatment of graft-versus-host disease: evidence and opinion.Ther Adv Hematol. 2013 Oct;4(5):320-34. doi: 10.1177/2040620713490316. Ther Adv Hematol. 2013. PMID: 24082993 Free PMC article.
-
Graft-versus-host disease: part I. Pathogenesis and clinical manifestations of graft-versus-host disease.J Am Acad Dermatol. 2012 Apr;66(4):515.e1-18; quiz 533-4. doi: 10.1016/j.jaad.2011.11.960. J Am Acad Dermatol. 2012. PMID: 22421123 Free PMC article.
-
Chronic GvHD NIH Consensus Project Biology Task Force: evolving path to personalized treatment of chronic GvHD.Blood Adv. 2023 Sep 12;7(17):4886-4902. doi: 10.1182/bloodadvances.2022007611. Blood Adv. 2023. PMID: 36322878 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials